Revvity, Inc. (LON:0KHE)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 8.40B |
| Revenue (ttm) | 2.14B |
| Net Income (ttm) | 221.40M |
| Shares Out | n/a |
| EPS (ttm) | 1.82 |
| PE Ratio | 37.94 |
| Forward PE | 18.70 |
| Dividend | 0.22 (0.23%) |
| Ex-Dividend Date | Jul 18, 2025 |
| Volume | 2 |
| Average Volume | 212 |
| Open | 94.18 |
| Previous Close | 94.32 |
| Day's Range | 94.18 - 95.17 |
| 52-Week Range | 88.16 - 129.08 |
| Beta | 0.97 |
| RSI | 46.82 |
| Earnings Date | Jul 31, 2025 |
About Revvity
Revvity, Inc. provides health sciences solutions, technologies, and services worldwide. The company’s Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and DNA sequencing services. Its Diagnostics segment offers instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for tes... [Read more]
Financial Performance
In 2024, Revvity's revenue was $2.76 billion, an increase of 0.16% compared to the previous year's $2.75 billion. Earnings were $270.39 million, a decrease of -60.99%.
Financial numbers in USD Financial StatementsNews
Revvity to Hold Earnings Call on Monday, July 28, 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its second quarter 2025 financial results prior to market open on Monday, July 28, 2025. The Company w...
Peering Into Revvity's Recent Short Interest
Revvity's (NYSE: RVTY) short percent of float has fallen 3.26% since its last report. The company recently reported that it has 5.63 million shares sold short , which is 6.83% of all regular shares t...
Revvity Introduces New IVD Reference Standards for Monitoring Oncology Diagnostic Testing Workflows
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced the launch of three Mimix™ reference standards for IVD use, designed for monitoring of next-generation sequencing (NGS) or ...
Is the Market Bullish or Bearish on Revvity?
Revvity's (NYSE: RVTY) short percent of float has risen 8.41% since its last report. The company recently reported that it has 5.11 million shares sold short , which is 6.19% of all regular shares th...
Revvity's EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced the launch of its new IDS i20™ analytical random access platform from EUROIMMUN, enabling full automation of chemiluminesce...
Global Preeclampsia Diagnostics Market to Exhibit Growth at a CAGR of ~4% by 2032 | DelveInsight
New York, USA, May 14, 2025 (GLOBE NEWSWIRE) -- Global Preeclampsia Diagnostics Market to Exhibit Growth at a CAGR of ~4% by 2032 | DelveInsight The expansion of the preeclampsia diagnostics market is...
Revvity: Despite Facing Multiple Headwinds, Shares Are A Buy
Revvity to Present at Upcoming Investor Conferences
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: Bank of America Global Healthcare Conference 2025 Tuesday, May 13, 2...
Revvity, Inc. (RVTY) Q1 2025 Earnings Call Transcript
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2193418274-c2ebb9f6602b4d848da8627052e824f1.jpg)
Biotech Firm Revvity Reports Better-Than-Expected Earnings
Revvity reported first-quarter earnings that topped analysts' estimates.
Earnings Summary: Revvity (RVTY) reports higher revenue and earnings for Q1 2025
Revvity, Inc. (NYSE: RVTY), a provider of health science solutions and technologies, on Monday reported an increase in revenue and adjusted profit for the first quarter of 2025. Revvity reported […] T...
Revvity, Inc. 2025 Q1 - Results - Earnings Call Presentation
Life Science Tools Maker Revvity Delivers Strong Q1 Earnings Despite Evolving Macroeconomic Backdrop
Revvity Inc. (NYSE: RVTY) stock is trading higher on Monday after the company reported better-than-expected first-quarter 2025 earnings . The Waltham, Massachusetts-based company reported first-quart...
Life Science Tools Maker Revvity Delivers Strong Q1 Earnings Despite Evolving Macroeconomic Backdrop
Revvity Inc. RVTY stock is trading higher on Monday after the company reported better-than-expected first-quarter 2025 earnings.
Revvity beats quarterly estimates on steady demand for medical equipment
Revvity reported first-quarter results above Wall Street estimates and maintained its full-year profit forecast on Monday, helped by steady demand from biotech clients for medical equipment used for d...
Revvity Non-GAAP EPS of $1.01 beats by $0.06, revenue of $665M beats by $3.34M
Revvity (RVTY) Q1 earnings exceed estimates with $1.01 EPS and $665M revenue. Updated 2025 guidance reflects growth.
Revvity Announces Financial Results for the First Quarter of 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the first quarter ended March 30, 2025. The Company reported GAAP earnings per share of $0.35, as comp...
Earnings Scheduled For April 28, 2025
Companies Reporting Before The Bell • Guardforce AI Co (NASDAQ: GFAI) is projected to report earnings for its Fiscal Year 2024. • Bright Scholar Education (NYSE: BEDU) is expected to report earnings...
Revvity Q1 2025 Earnings Preview
Earnings Preview For Revvity
Revvity (NYSE: RVTY) will release its quarterly earnings report on Monday, 2025-04-28. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Revvity to report an earnin...
Revvity Board Declares Quarterly Dividend
WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 8, 2...
Watchmaker Genomics and Revvity Team to Automate and Streamline NGS Library Preparation
BOULDER, Colo.--(BUSINESS WIRE)-- #NGS--Watchmaker Genomics, a leader in high-performance genomics solutions, today announced an important milestone in providing comprehensive and robust automated sol...
Revvity Fuels the Future of Cancer Science with New Research Solutions
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc., is set to unveil the VivoJect™ Image-Guided Injection System as part of its distinguished cancer research and discovery portfolio at the AACR Annual Mee...
Revvity to Hold Earnings Call on Monday, April 28, 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its first quarter 2025 financial results prior to market open on Monday, April 28, 2025. The Company w...
What's Going On With Revvity Stock Today?
Revvity, Inc. (NYSE: RVTY) shares are trading higher on Wednesday. The company announced today that the U.S. Food and Drug Administration has approved its Auto-Pure 2400 liquid handling platform, int...